Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

Cancer Immunology, Immunotherapy

Volumn 64, Issue 7, 2015, Pages 817-829

  Burga, Rachel A ^a,b   Thorn, Mitchell ^a,b   Point, Gary R ^a,b   Guha, Prajna ^a,b   Nguyen, Cang T ^a,b   Licata, Lauren A ^a,b   DeMatteo, Ronald P ^c   Ayala, Alfred ^d   Joseph Espat, N ^a,b   Junghans, Richard P ^a   Katz, Steven C ^a,b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

CAR T; GM CSF; Immunosuppression; Liver metastases; MDSC

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; STAT3 PROTEIN; CARCINOEMBRYONIC ANTIGEN; CD274 PROTEIN, MOUSE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; FLOW CYTOMETRY; LIVER METASTASIS; MACROPHAGE; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENECTOMY; SUPPRESSOR CELL; T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; CD8+ T LYMPHOCYTE; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; SECONDARY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD274; CARCINOEMBRYONIC ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID CELLS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN;

EID: 84933178008     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1692-6     Document Type: Article

References (53)

1. Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN (2007) New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 1(1):20–27
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580. doi:10.1200/JCO.2007.11.0833
3. Grothey A, Sargent D (2005) Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23(36):9441–9442. doi:10.1200/JCO.2005.04.4792
4. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059–2069. doi:10.1200/JCO.2003.11.126
5. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D’Angelica M, DeMatteo RP (2009) T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 16(9):2524–2530. doi:10.1245/s10434-009-0585-3
6. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y, D’Angelica MI, DeMatteo RP (2013) Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 20(3):946–955. doi:10.1245/s10434-012-2668-9
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–23. doi: 10.1056/NEJMoa1003466
8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–22. doi: 10.1056/NEJMoa1001294
9. Davila ML, Kloss CC, Gunset G, Sadelain M (2013) CD19 CAR-targeted T cells induce long-term remission and B cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 8(4):e61338. doi:10.1371/journal.pone.0061338
10. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509–1518. doi:10.1056/NEJMoa1215134
11. Lo AS, Ma Q, Liu DL, Junghans RP (2010) Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 16(10):2769–2780. doi:10.1158/1078-0432.CCR-10-0043
12. Midiri G, Amanti C, Benedetti M, Campisi C, Santeusanio G, Castagna G, Peronace L, Di Tondo U, Di Paola M, Pascal RR (1985) CEA tissue staining in colorectal cancer patients. A way to improve the usefulness of serial serum CEA evaluation. Cancer 55(11):2624–2629
13. Emtage PC, Lo AS, Gomes EM, Liu DL, Gonzalo-Daganzo RM, Junghans RP (2008) Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res 14(24):8112–8122. doi:10.1158/1078-0432.CCR-07-4910
14. Saied A, Licata L, Burga RA, Thorn M, McCormack E, Stainken BF, Assanah EO, Khare PD, Davies R, Espat NJ, Junghans RP, Katz SC (2014) Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Ther 21(11):457–462. doi:10.1038/cgt.2014.50
15. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166(1):678–689
16. Katz SC, Pillarisetty VG, Bleier JI, Kingham TP, Chaudhry UI, Shah AB, DeMatteo RP (2005) Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors. Hepatology 42(2):293–300. doi:10.1002/hep.20795
17. Hochst B, Schildberg FA, Sauerborn P, Gabel YA, Gevensleben H, Goltz D, Heukamp LC, Turler A, Ballmaier M, Gieseke F, Muller I, Kalff J, Kurts C, Knolle PA, Diehl L (2013) Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol 59(3):528–535. doi:10.1016/j.jhep.2013.04.033
18. Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16(1):53–65. doi:10.1016/j.semcancer.2005.07.005
19. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49–59. doi:10.1007/s00262-008-0523-4
20. Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA (2013) Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 122(8):1399–1410. doi:10.1182/blood-2013-04-495531
21. Sharpe AH, Wherry WJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8(3):239–245
22. Ghosh CC, Mukherjee A, David S, Knaus UG, Stearns-Kurosawa DJ, Kurosawa S, Parikh SM (2012) Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax. Proc Natl Acad Sci USA 109(25):10024–10029. doi:10.1073/pnas.1120755109
23. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD (2012) Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72(4):876–886. doi:10.1158/0008-5472.CAN-11-1792
24. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP (1999) Unopposed production of granulocyte–macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162(10):5728–5737
25. Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G (2013) Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood 121(10):1740–1748. doi:10.1182/blood-2012-06-436568
26. John LB, Devaud C, Duong CM, Yong C, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19(20):5636–5646. doi:10.1158/1078-0432.CCR-13-0458
27. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O’Brien S, Faderl S, Keating M, Estrov Z (2014) STAT3-activated GM-CSFRalpha translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res 12(9):1267–1282. doi:10.1158/1541-7786.MCR-13-0652-T
28. Wolfle SJ, Strebovsky J, Bartz H, Sahr A, Arnold C, Kaiser C, Dalpke AH, Heeg K (2011) PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 41(2):413–424. doi:10.1002/eji.201040979
29. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI (2005) Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65(20):9525–9535. doi:10.1158/0008-5472.CAN-05-0529
30. Ilkovitch DLD (2009) The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 69(13):5514–5521
31. Zhao L, Lim SY, Gordon-Weeks AN, Tapmeier TT, Im JH, Cao Y, Beech J, Allen D, Smart S, Muschel RJ (2013) Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology 57(2):829–839. doi:10.1002/hep.26094
32. Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56(5):739–745. doi:10.1007/s00262-006-0272-1
33. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24(6):302–306
34. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM (2002) Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168(2):689–695
35. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20(10):1819–1828. doi:10.1038/sj.leu.2404366
36. Greten TF, Manns MP, Korangy F (2011) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11(7):802–807. doi:10.1016/j.intimp.2011.01.003
37. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. doi:10.1038/nri2506
38. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH (2012) Tumor-derived granulocyte–macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822–835. doi:10.1016/j.ccr.2012.04.025
39. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H (2013) GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res 73(21):6413–6423. doi:10.1158/0008-5472.CAN-12-4124
40. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6):836–847. doi:10.1016/j.ccr.2012.04.024
41. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V (2010) Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40(1):22–35. doi:10.1002/eji.200939903
42. Katz SC, Pillarisetty VG, Bleier JI, Shah AB, DeMatteo RP (2004) Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol 173(1):230–235
43. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90(8):3539–3543
44. Nemunaitis J (2003) GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J Control Release 91(1–2):225–231
45. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, Collins SL, Petruzzelli GJ (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte–macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74(1):69–74
46. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I (2004) High-dose granulocyte–macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64(17):6337–6343. doi:10.1158/0008-5472.CAN-04-0757
47. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169(10):5538–5545
48. Gaudreau S, Guindi C, Menard M, Benabdallah A, Dupuis G, Amrani A (2010) GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes. Cell Immunol 265(1):31–36. doi:10.1016/j.cellimm.2010.06.010
49. Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F (2002) In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J 16(2):225–227. doi:10.1096/fj.01-0633fje
50. Mauldin IS, Tung KS, Lorenz UM (2012) The tyrosine phosphatase SHP-1 dampens murine Th17 development. Blood 119(19):4419–4429. doi:10.1182/blood-2011-09-377069
51. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783–3797. doi:10.4049/jimmunol.1201449
52. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H (2013) PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation 10:111. doi:10.1186/1742-2094-10-111
53. Katz SC, Burga R, Wang L, Mooring W, Davies R, Stainken BF, Assanah EO, Khare P, Ma Q, Espat NJ, Junghans RP (2014) Hepatic Immunotherapy for Metastases (HITM): a phase I trial of anti-CEA genetically modified T cells for unresectable adenocarcinoma. Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ